Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-02-15
2009-08-11
Badio, Barbara P (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S178000, C514S182000, C552S612000
Reexamination Certificate
active
07572781
ABSTRACT:
The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to the subject invention appear to be highly advantageous as prodrugs to provide protection and/or treatment against ocular disorders. These prodrugs confer lipid solubility optimal for transocorneal penetration and are readily converted to endogenous reducing agents into active phenolic A-ring steroid compounds. To the extent that these prodrugs have reduced feminizing effects and systemic toxicity, they would be expected to be quite advantageous for protecting or treating the eye against ocular disorders such as cataract or glaucoma without undesired (systemic) side effects).
REFERENCES:
patent: 2910486 (1959-10-01), Jiu
patent: 2950291 (1960-08-01), Jiu
patent: 5041434 (1991-08-01), Lubkin
patent: 5108996 (1992-04-01), Claussner et al.
patent: 5395831 (1995-03-01), Gemmill, Jr. et al.
patent: 5405944 (1995-04-01), Suzuki et al.
patent: 5552395 (1996-09-01), Gemmill, Jr. et al.
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5646136 (1997-07-01), Petrow et al.
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5891878 (1999-04-01), Beasley et al.
patent: 6096733 (2000-08-01), Lubkin
patent: 6197833 (2001-03-01), Simpkins et al.
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6319914 (2001-11-01), Simpkins et al.
patent: 7186707 (2007-03-01), Prokai et al.
patent: 2002/0016340 (2002-02-01), Rosati
patent: 2003/0050295 (2003-03-01), Pang
patent: 2003/0105167 (2003-06-01), Dykens et al.
patent: 2004/0214806 (2004-10-01), Pang et al.
patent: 196 54 750 (1998-07-01), None
patent: WO 02/36605 (2002-05-01), None
patent: WO 03/084978 (2003-10-01), None
Beers, M.H. and R. Berkow, Editors, The Merck Manual of diagnosis and therapy, pp. 471-473 and pp. 1942-1944 (1999) Merck Research Laboratories, Whitehouse Station, N.J. USA.
Bigsby, R.M. et al. “Protective Effects of Estrogen in a Rat Model of Age-Related Cataracts”Proc. Natl. Acad. Sci., Aug. 1999, pp. 9328-9332, vol. 96.
Breuer, H. and Koster, G., “Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level”,Journal of Steroid Biochemistry, 1974, pp. 961-967, vol. 5, Pergamon Press, Great Britain.
Galdecki, Z. et al. , “Structure of 2,4-Dibromo-10β, 17β-dihydroxy-1,4-estradien-3-one”,Acta Cryst., 1987, pp. 967-968, vol. C43, International Union of Crystallography.
Hiemke, C. et al., “Actions of Sex Hormones on the Brain”,Prog. Neuro-Psychopharmacol&Biol.Psychiat., 1992, pp. 377-388, vol. 16, Pergamon Press, Great Britain.
Kupfer, R. et al., “Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site”,Biochemistry, 2001, pp. 11490-11501, vol. 40, American Chemical Society.
Liang, Y. et al., “Membrane Fluidity Effects of Estratienes”,Brain Research Bulletin, 2001, pp. 661-668, vol. 54, No. 6, Elsevier Science Inc., USA.
Lunn et al., “The adamantyl carbonium ion as a dehydrogenating agent, its reactions with estrone,”Tetrahedron, 1968, vol. 24, No. 23, pp. 6773-6776.
Lupon, P. et al. (1983) “Photooxygenierung von Oestrogenen: Eine Neu 19-Norsteroid-Synthese” Verlagsgesellschaft, Weinheim, DE, vol. 95, No. 9, p. 757.
McCullough, L. and Hurn, P., “Estrogen and Ischemic Neuroprotection: an integrated view”,Trends in Endocrinology and Metabolism, Jul. 2003, pp. 228-235, vol. 14, No. 5, Elsevier Science Inc.
McKinney, K.A. et al. “Hormone Replacement Therapy and the Eye”Journal of the British Menopause Society, Mar. 2000, pp. 15-17, vol. 6, No. 1.
Milic, D. et al., “Structure and Reactivity of Steroidal Quinones”,J. Serb. Chem. Soc., 1997, pp. 755-768, vol. 62, No. 9.
Milic, D. et al., “The Synthesis and Biological Evaluation of A-Ring Substituted Steroidalp-Quinones”,Tetrahedron, 1997, pp. 14073-14084, vol. 53, No. 41, Elsevier Science Ltd., Great Britain.
Milic, D. et al., “X-Ray Crystal Structure of 10β-Hydroxy-4β,5β-expoxyerstr-1-en-3,17-dione and Antitumor Activity of its Congeners”,Molecules, 1999, pp. 338-352, vol. 4, MDPI.
Nilsen, J. and Brinton R., “Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling”,PNAS, Sep. 2, 2003, pp. 10506-10511, vol. 100, No. 18.
Nilsen, J. and Brinton, R., “Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate”,Endocrinology, 2002, pp. 205-212, vol. 143, No. 1, The Endocrine Society, USA.
Numazawa, M. et al., “Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nor Steroids”,Chem. Pharm Bull., 1989, pp. 2058-2062, vol. 37, No. 8, Pharmaceutical Society of Japan.
Ohe, T. et al., “Novel Metabolic Pathway of Estrone and 17β-Estradiol Catalyzed by Cytochrome P-450”,Drug Metabolism and Disposition, 2000, pp. 110-112, vol. 28, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.
Prokai-Tatrai, K. and Prokai, L., “Modifying peptide properties by prodrug design for enhanced transport into the CNS”,Progress in Drug Research, 2003, pp. 155-188, vol. 61, Birkhäuser Verlag, Basel (Switzerland).
Prokai, L. et al. “Chemical Shield Mechanism for Estrogen Neuroprotection: Steroidal Quinols as new Molecular Leads”Abstracts of Paper. At the National Meeting, American Chemical Society, Mar. 23-27, 2003, vol. 225, No. 1/2.
Prokai, L. et al., “Quinol-based cyclic antioxidant mechanism in estrogen neuroprotein”,PNAS, Sep. 30, 2003, pp. 11741-11746, vol. 100, No. 20.
Prokai, L. et al., “Short Communication: Quinol-Based Metabolic Cycle for Estrogen in Rat Liver Microsomes”,Drug Metabolism and Disposition, 2003, pp. 701-704, vol. 31, No. 6, The American Society for Pharmacology and Experimental Therapeutics, USA.
Prokai, L. et al., “Synthesis and Biological Evaluation of 17β-Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress”,J. Med. Chem., 2001, pp. 110-114, vol. 44, American Chemical Society.
Prokai, L. et al., “Targeting Drugs to the Brain by Redox Chemical Delivery Systems”,Med. Res. Rev., 2000, pp. 367-416, vol. 20, No. 5, John Wiley & Sons, Inc.
Sedee, A.G. J. et al. (1983) “A sintesis for p-quinol compounds from phenols fused with other saturated rings”Tetrahedron Letters24(51):5779-5780.
Solaja, B. et al., “A Novelm-CPBA Oxidation:p-Quinols and Epoxyquinols from Phenols”,Tetrahedron Letters, 1996, pp. 3765-3768, vol. 37, No. 2kl1, Elsevier Science Ltd., Great Britain.
Agarwal Neeraj
Prokai Katalin
Prokai Laszlo
Simpkins James
Badio Barbara P
Saliwanchik Lloyd & Saliwanchik
University of Florida
University of North Texas Health Science Center
LandOfFree
Prodrugs for use as ophthalmic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs for use as ophthalmic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for use as ophthalmic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084618